I’m not in total agreement on this one Kens.
Only having just become a revenue generating biotech to have an income source in the 10s of millions per annum and ~$230m in the bank is quite remarkable.
Companies like another of my early stage favourites PYC have no option but to raise money like they just did ($70m+)
Neuren now makes that.
To have another source of income, yes whilst ideal, would be well beyond expectations at this early stage of commercialisation and therefore not desperately needed.
Acadia needs the revenue probably more so now so they’ll leave no stone unturned to ensure the Daybue revenue is maintained and increased.
I’m not in total agreement on this one Kens. Only having just...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.70 |
Change
0.520(2.71%) |
Mkt cap ! $2.515B | |||
| Open | High | Low | Value | Volume |
| $19.39 | $19.84 | $19.28 | $5.675M | 288.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1531 | $19.66 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.81 | 557 | 1 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$19.70 |
Change
0.520 ( 2.59 %) |
||||
| Open | High | Low | Volume | ||
| $19.50 | $19.84 | $19.28 | 87628 | ||
| Last updated 15.59pm 03/05/2024 ? | |||||
| NEU (ASX) Chart |